DNA Modification Methylases
"DNA Modification Methylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that are part of the restriction-modification systems. They are responsible for producing a species-characteristic methylation pattern, on either adenine or cytosine residues, in a specific short base sequence in the host cell's own DNA. This methylated sequence will occur many times in the host-cell DNA and remain intact for the lifetime of the cell. Any DNA from another species which gains entry into a living cell and lacks the characteristic methylation pattern will be recognized by the restriction endonucleases of similar specificity and destroyed by cleavage. Most have been studied in bacterial systems, but a few have been found in eukaryotic organisms.
| Descriptor ID |
D015254
|
| MeSH Number(s) |
D08.811.150.240 D08.811.913.555.500.350
|
| Concept/Terms |
DNA Modification Methylases- DNA Modification Methylases
- Methylases, DNA Modification
- Modification Methylases, DNA
- Modification Methylases
- Methylases, Modification
- DNA Modification Methyltransferases
- Methyltransferases, DNA Modification
- Modification Methyltransferases, DNA
|
Below are MeSH descriptors whose meaning is more general than "DNA Modification Methylases".
Below are MeSH descriptors whose meaning is more specific than "DNA Modification Methylases".
This graph shows the total number of publications written about "DNA Modification Methylases" by people in this website by year, and whether "DNA Modification Methylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "DNA Modification Methylases" by people in Profiles.
-
Fleming JL, Pugh SL, Fisher BJ, Lesser GJ, Macdonald DR, Bell EH, McElroy JP, Becker AP, Timmers CD, Aldape KD, Rogers CL, Doyle TJ, Werner-Wasik M, Bahary JP, Yu HM, D'Souza DP, Laack NN, Sneed PK, Kwok Y, Won M, Mehta MP, Chakravarti A. Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma. JCO Precis Oncol. 2021; 5.
-
Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018 10 01; 4(10):1405-1409.
-
Quagliano A, Gopalakrishnapillai A, Barwe SP. Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia. Leuk Res. 2017 05; 56:36-43.
-
Watson CJ, Horgan S, Neary R, Glezeva N, Tea I, Corrigan N, McDonald K, Ledwidge M, Baugh J. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis. J Cardiovasc Pharmacol Ther. 2016 Jan; 21(1):127-37.
-
McCorkell KA, Mancini R, Siprashvili Z, Barnoski BL, Iliopoulos D, Siracusa LD, Zanesi N, Croce CM, Fong LY, Druck T, Huebner K. Influence of a nonfragile FHIT transgene on murine tumor susceptibility. Cytogenet Genome Res. 2007; 118(2-4):196-203.
-
Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, McCorkell KA, Lakshman TV, Collins JE, Wachsberger P, Friedberg JS, Huebner K. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer. 2007 Jan 01; 120(1):24-31.